|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 309.60 DKK | +1.24% |
|
-2.33% | -50.40% |
| 12-05 | Sector Update: Health Care Stocks Lower Late Afternoon | MT |
| 12-05 | Sector Update: Health Care Stocks Decline Friday Afternoon | MT |
| Capitalization | 1,376B 214B 184B 173B 161B 297B 19,284B 323B 2,018B 779B 9,108B 804B 787B 33,302B | P/E ratio 2025 * |
13.4x | P/E ratio 2026 * | 13.3x |
|---|---|---|---|---|---|
| Enterprise value | 1,477B 230B 198B 185B 173B 319B 20,703B 347B 2,167B 837B 9,778B 863B 845B 35,752B | EV / Sales 2025 * |
4.8x | EV / Sales 2026 * | 4.79x |
| Free-Float |
70.25% | Yield 2025 * |
3.76% | Yield 2026 * | 3.73% |
Last Transcript: Novo Nordisk A/S
| 1 day | +1.24% | ||
| 1 week | -2.33% | ||
| Current month | -2.33% | ||
| 1 month | +0.86% | ||
| 3 months | -11.54% | ||
| 6 months | -36.86% | ||
| Current year | -50.40% |
| 1 week | 299.35 |  | 317.65 |
| 1 month | 266.9 | | 326.4 |
| Current year | 266.9 | | 675.2 |
| 1 year | 266.9 | | 798.1 |
| 3 years | 266.9 | | 1,033.2 |
| 5 years | 207.22 | | 1,033.2 |
| 10 years | 109.1 | | 1,033.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 07/08/2025 | |
| Director of Finance/CFO | 54 | 15/02/2018 | |
Martin Lange
CTO | Chief Tech/Sci/R&D Officer | 55 | 07/08/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kasim Kutay
BRD | Director/Board Member | 60 | 23/03/2017 |
| Director/Board Member | 50 | 22/03/2018 | |
Thomas Rantzau
BRD | Director/Board Member | 53 | 22/03/2018 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 21.31% | 1,412 M€ | +0.52% | - |
| 10.45% | 4 M€ | +20.34% | - |
| 5.4% | 26 M€ | +11.73% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.24% | -2.33% | -60.59% | -30.82% | 214B | |
| -0.41% | -6.06% | +22.21% | +174.14% | 905B | |
| -0.27% | -2.41% | +35.24% | +14.67% | 487B | |
| -1.15% | -0.71% | +28.32% | +38.09% | 400B | |
| +0.26% | +1.14% | +20.97% | +1.87% | 330B | |
| +0.58% | -2.73% | +27.58% | +21.90% | 281B | |
| +0.19% | +2.49% | +19.23% | +25.56% | 255B | |
| -1.16% | -4.87% | -3.27% | -8.45% | 248B | |
| -3.02% | -4.51% | +21.03% | +16.45% | 178B | |
| -1.14% | -3.67% | +31.57% | +37.81% | 150B | |
| Average | -0.49% | -2.37% | +14.23% | +29.12% | 344.69B | |
| Weighted average by Cap. | -0.40% | -2.83% | +18.23% | +56.02% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 308B 47.93B 41.2B 38.6B 35.98B 66.45B 4,314B 72.28B 451B 174B 2,037B 180B 176B 7,450B | 307B 47.84B 41.13B 38.53B 35.91B 66.33B 4,306B 72.14B 451B 174B 2,034B 180B 176B 7,436B |
| Net income | 103B 16.01B 13.76B 12.89B 12.02B 22.19B 1,441B 24.14B 151B 58.23B 681B 60.09B 58.81B 2,488B | 101B 15.77B 13.55B 12.7B 11.83B 21.86B 1,419B 23.77B 148B 57.34B 670B 59.17B 57.91B 2,450B |
| Net Debt | 101B 15.77B 13.55B 12.7B 11.83B 21.86B 1,419B 23.78B 149B 57.34B 670B 59.18B 57.92B 2,451B | 97.02B 15.11B 12.99B 12.17B 11.34B 20.95B 1,360B 22.79B 142B 54.96B 642B 56.72B 55.51B 2,349B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/12/25 | 309.60 kr | +1.24% | 5,369,194 |
| 04/12/25 | 305.80 kr | +0.66% | 6,173,721 |
| 03/12/25 | 303.80 kr | -1.06% | 4,265,824 |
| 02/12/25 | 307.05 kr | -2.35% | 4,705,597 |
| 01/12/25 | 314.45 kr | -0.80% | 5,405,519 |
Delayed Quote Nasdaq Copenhagen, December 05, 2025 at 07:20 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVO B Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition